Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.
10.1016/j.apsb.2021.11.013
- Author:
Antonio SEGOVIA-ZAFRA
1
;
Daniel E DI ZEO-SÁNCHEZ
1
;
Carlos LÓPEZ-GÓMEZ
2
;
Zeus PÉREZ-VALDÉS
1
;
Eduardo GARCÍA-FUENTES
2
;
Raúl J ANDRADE
1
;
M Isabel LUCENA
1
;
Marina VILLANUEVA-PAZ
1
Author Information
1. Unidad de Gestión Clínica de Gastroenterología, Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga 29071, Spain.
2. Unidad de Gestión Clínica de Aparato Digestivo, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Málaga 29010, Spain.
- Publication Type:Review
- Keywords:
Drug-induced liver injury;
Immune response;
Mechanisms;
Mitochondrial damage;
Oxidative stress;
Personalized medicine;
Preclinical models
- From:
Acta Pharmaceutica Sinica B
2021;11(12):3685-3726
- CountryChina
- Language:English
-
Abstract:
Idiosyncratic drug-induced liver injury (iDILI) encompasses the unexpected harms that prescription and non-prescription drugs, herbal and dietary supplements can cause to the liver. iDILI remains a major public health problem and a major cause of drug attrition. Given the lack of biomarkers for iDILI prediction, diagnosis and prognosis, searching new models to predict and study mechanisms of iDILI is necessary. One of the major limitations of iDILI preclinical assessment has been the lack of correlation between the markers of hepatotoxicity in animal toxicological studies and clinically significant iDILI. Thus, major advances in the understanding of iDILI susceptibility and pathogenesis have come from the study of well-phenotyped iDILI patients. However, there are many gaps for explaining all the complexity of iDILI susceptibility and mechanisms. Therefore, there is a need to optimize preclinical human
